• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing

Trending Tickers: Z, VRX, BIIB, ALXN

U.S. indices are up as oil continues its climb past $50 a barrel.
By REAL MONEY
Jun 07, 2016 | 12:37 PM EDT
Stocks quotes in this article: Z, VRX, BIIB, ALXN

The U.S. market indices traded up slightly in midday trading Tuesday as oil continued its months-long climb past $50 a barrel. The Dow and S&P 500 edged up 0.4% and 0.3%, respectively, as the Nasdaq was unchanged.

Crude oil prices traded up 0.7% to $50.05 a barrel, based on U.S. benchmark West Texas Intermediate.

Shares of Zillow (Z) traded up about 5% in midday trading, after the Seattle-based online real-estate database announced it has reached a settlement with rival Move for $130 million.

Investors appear to be relieved that Zillow was able to circumvent a looming trial this month, in which Move and the National Association of Realtors were seeking up to $2 billion in damages over allegations that Zillow executives brought trade secrets with them in their departure from Move in 2014. 

Meanwhile, Valeant Pharmaceuticals (VRX) stock was down 12% after the beleaguered Canadian drugmaker posted a first-quarter earnings miss and cut its 2016 guidance.

Valeant posted adjusted earnings per share of $1.27, missing analyst forecasts by about 7%, and Valeant's new CEO, Joseph Papa, cut the drugmaker's earnings guidance for 2016 to a range of $6.60 to $7 per share, down from a previous range of $8.50 and $9.50 in March.

"The first quarter's results reflect, in part, the impact of significant disruption this organization has faced over the past nine months," Papa said in a statement Tuesday, marking his first earnings report with Valeant since replacing Michael Pearson last month.

Drugmakers Biogen (BIIB) and  Alexion Pharmaceuticals (ALXN) also traded down 12% and 11%, respectively, on news that promising new products failed clinical trials.

Biogen's experimental drug aimed to treat multiple sclerosis, Opicinumab, failed a mid-staged trial, prompting investors to take flight from the disappearance of what had been viewed as a potential sales driver. (Biogen stock is a holding of Jim Cramer's Action Alerts PLUS charitable trust.)

In the phase-2 study, Opicinumab missed "the primary endpoint," Biogen said in a statement, noting "evidence of a clinical effect with a complex, unexpected dose-response was observed." 

"The 'novel' therapy which had been touted as the future of MS and the first drug capable of reversing the progression of the disease turned out to be yet another disaster in Biogen's history of overpromising and under- delivering," Jim Cramer and  Action Alerts PLUS co-manager Jack Mohr said in a Tuesday report.

"Fortunately, we have repeatedly, explicitly distanced ourselves from the stock, given management's incoherent strategy and increasingly speculative nature of the investment," they added.

And New Haven, Conn.-based Alexion also disappointed shareholders with a post-market report Monday that final-stage trials of Soliris, a developing medication aimed to treat muscle weakness, yielded lackluster results.

Alexion said in a statement the study also missed its "primary endpoint" and that cases of successful responses to Soliris "missed statistical significance."

-- written by James Passeri

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from owning individual securities.

Action Alerts PLUS, which Cramer co-manages as a charitable trust, is long Biogen stock.

TAGS: Investing | U.S. Equity

More from Investing

On Surface Market Appeared Quiet, but Underneath Fireworks Sparked

James "Rev Shark" DePorre
Aug 16, 2022 4:37 PM EDT

Short-squeezes, stock rotations and parabolic S&P moves rocked the day.

You Bet Your BP I'd Be a Buyer

Mark Sebastian
Aug 16, 2022 2:32 PM EDT

With oil down over the last two days, BP's stock has held up.

Doug Kass: We May Now Be Approaching Another Important Top in the Market

Doug Kass
Aug 16, 2022 1:30 PM EDT

To justify buying at today's prices means that one expects a new Bull Market leg - something I remain dubious of.

Cisco, Long a Steady Tech Stock, Is Under the Microscope Ahead of Earnings

Brad Ginesin
Aug 16, 2022 12:45 PM EDT

Some top analysts are flashing a yellow light on the network equipment maker ahead of its quarterly report and amid tightening competition. But is caution really warranted for long-term investors?

2 Big-Name, Single-Stock ETFs With a Foreign Twist Could Be on the Horizon

Mark Abssy
Aug 16, 2022 12:00 PM EDT

The potential offerings from Roundhill aren't geared solely to the retail investor but also could interest smaller institutions and other ETF issuers.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:23 PM EDT STEPHEN GUILFOYLE

    We're Cleaning Out This Retailer From the Bullpen

    Check out the latest moves in TheStreet's Stocks U...
  • 10:24 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    To Improve Your Trading and Investing, Spend More ...
  • 08:44 AM EDT PETER TCHIR

    CPI Beats Expectations, But Maybe Not the 'Whisper'?

    Slightly better-than-expected inflation across the...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login